Moderna, Inc. vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF — how do they compare? Moderna, Inc. trades at $60.21 (market cap $24.18B), while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $17.91. The key difference: Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.
| MRNA | PDBC | |
|---|---|---|
Market Cap | $24.18B | — |
Sector | Health | — |
52-Week High | $81.80 | $18.91 |
52-Week Low | $22.36 | $12.90 |
Enterprise Value | $20.33B | — |
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
No Aura AI signal available yet.
Trailing returns across standard periods
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →